Substitute for form 1449A/PTO				Complete if Known			
Subs	stitute for form 1449AVF1O			Application Number	10/591,743		
				Filing Date	Unassigned		
	FORMATION DISC			First Named Inventor	Alley, Stephen C.		
STATEMENT BY APPLICANT				Art Unit	Unassigned		
	(Use as many sheets as ne	racean	d)	Examiner Name	Unassigned		
Sheet	1	of	3	Attorney Docket Number	018891-000720US		

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number Kind Code <sup>2 (F known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	12	US-2005/0152894 A1	07-14-2005	Krummen et al.	
			i		

	FOREIGN PATENT DOCUMENTS									
Examiner I	Cite	F	oreign Patent Do	cument	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T <sup>6</sup>		
IIIIIais		Country Code <sup>3</sup>	Number⁴	Kind Code <sup>5</sup> (if known)			or Relevant Figures Appear	<u> </u>		
	13	WO	2006/034488	A2	03-30-2006	Eigenbrot et al.				
	14	WO	2006/065533	A2	06-22-2006	McDonagh et al.				
	15	WO	2006/065533	A3	06-22-2006	McDonagh et al.				
			•••••		••••••					
······			***************************************	***************************************	••••••					

EXAMINICI I			
Signature /Phuong Huynh/ Considered 12/02/2009	 /Phuong Huynh/	Date Considered	12/02/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.H./61475562 v1

Substitute	for form 1449B/PTC	)		Complete if Known			
				Application Number	10/591,743 Unassigned Alley, Stephen C.		
INFO	RMATION	DISCLOS	SURE	Filing Date			
	TEMENT B			First Named Inventor			
	·			Art Unit	Unassigned		
	(Use as many she	ets as necessary)		Examiner Name	Unassigned		
Sheet	2	of	3	Attorney Docket Number	018891-000720US		

		NON PATENT LITERATURE DOCUME	ENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the art magazine, journal, serial, symposium, catalog, etc.), date, page and/or country where pub	e(s), volume-iss	ropriate), title of the item (book, ue number(s), publisher, city	T²			
	16	DORAL et al., "Role of Inter-Heavy and Light Chain Disulfide Bo Immunoglobulin IgG1," Molecular Immunology, 29(12):1487-149	nds in the Effect 1 (1992).	tor Functions of Human				
	17	FRANCISCO et al., " cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity," <u>Blood</u> , 102(4):1458-1465 (August 15, 2003).						
••••••	18	GILLIES et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," Hum. Antibod. Hybridomas, 1(1):47-54 (1990).						
	19	HAMANN et al., "Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 AntibodyCalicheamicin Conjugate for Treatment of Acute Myeloid Leukemia," <u>Bioconjugate Chem.</u> , 13:47-58 (2002).						
	20	International Search Report of 8/17/2006 for International Application PCT/US05/07239						
	21	LYONS et al., "Site-specific attachment to recombinant antibodies Eng., 3(8):703-708 (1990).	via introduced	surface cysteine residues," <u>Prot.</u>				
	22	OI et al., "Chimeric Antibodies," BioTechniques, 4(3):214-221 (1	1986).					
	23	Product description of Mylotarg® (gemtuzumab ozogamicin for Injection), by Wyeth Pharmaceuticals, Inc., 7/04 revision, pages 1-19.						
••••••	24	QU et al., "Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates," J. Immunological Methods, 213:131-144 (1998).						
	RODWELL et al., "Site-specific covalent modification of monoclonal antibodies: <i>In vitro</i> and <i>in vivo</i> evaluations," PNAS, 83:2632-2636 (April 1986).							
	26	SAITO et al., "Drug delivery strategy utilizing conjugation via rev reducing activities," <u>Advanced Drug Delivery Reviews</u> , 55:199-21	rersible disulfide 5 (2003).	linkages: role and site of cellular				
Examiner Signature	.1	/Phuong Huynh/	Date Considered	12/02/2009				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

61475562 v1

Substitute	for form 1449B/PT	го		Complete if Known		
				Application Number	10/591,743	
INFO	RMATION	N DISCLOS	SURE	Filing Date	Unassigned	
STATEMENT BY APPLICANT  (Use as many sheets as necessary)				First Named Inventor	Alley, Stephen C.	
				Art Unit	Unassigned	
				Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	018891-000720US	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	27	STIMMEL et al., "Site-specific Conjugation on Serine -> Cysteine Variant Monoclonal Antibodies," <u>J. Biol. Chem.</u> , 275(39):30445-30450 (2000).				
	28	SUN et al., "Reduction-Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides," <u>Bioconjugate Chem.</u> , 16:1282-1290 (2005).				
	29	Written Opinion of 8/17/06 for International Application PCT/US05/07239.				

	The state of the s		
Examiner Signature	/Phuong Huynh/	Date Considered	12/02/2009

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.